Biomarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO Cristin Hubbard - EVP and Chief Commercial Officer Greg Friberg - EVP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Jessica Fye - JPMorgan Cory Kasimov - Evercore Christopher Raymond - Piper Sandler Gena Wang - Barclays Julian Pino - Stifel Akash Tewari - Jefferies Eli Merle - UBS Kostas Biliouris - BMO Capital Markets Sadia Rahman - Wells Fargo Olivia Brayer - Cantor Fitzgerald Alex Hammond - Wolfe Research Operator Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call. All lines have been placed on mute to prevent any background noise.
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.49 per share a year ago.
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated $0.53.
BioMarin to Report Q4 Earnings: Here's What to Expect
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Growth Investors Will Love BioMarin (BMRN)
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
4 Stocks That Sport Impressive Interest Coverage Ratio
BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
